AT A GLANCE

04/14/2022

Coronavirus Disease 2019 (COVID-19)

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Please note: This scan is published on April 14, 2022 as April 15, 2022 is a statutory holiday

Table of Contents

New Content ........................................................................................................................................... 3
Public Health Agencies ............................................................................................................................ 3
  Public Health Agency of Canada | canada.ca ............................................................................................ 3
  BC Centre for Disease Control | bccdc.ca ......................................................................................... 4
  Institut national de santé publique ..................................................................................................... 4
  CDC: Centers for Disease Control and Prevention | cdc.gov ................................................................ 4
  ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ...................................... 5
  FDA: U.S. Food & Drug Administration | fda.gov ........................................................................ 5
  Public Health England | gov.uk .................................................................................................................. 5
  World Health Organization | who.int ........................................................................................................ 5
Other relevant government bodies / health care organizations ............................................................. 6
  CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu ........................................... 8
  National Collaborating Centre for Environmental Health | ncceh.ca ..................................................... 9
  Updated Daily ....................................................................................................................................... 9
  COVID-19 resources (case counts) | arcgis.com ............................................................................... 9
  COVID-19 Canada Open Data Working Group | COVID-19 CODWG .............................................. 9
  Johns Hopkins CCSE | systems.jhu.edu .................................................................................................. 9
  NextStrain | nextstrain.org ................................................................................................................... 9
Guidelines and Technical documents (updated weekly) ..................................................................... 10
Section I: General Guidelines ................................................................................................................ 10
Ontario / Canada Main Page
Reopening/Rebuilding Guidelines
Vaccinations- General
Vaccinations- Specific populations
Vaccinations- Adverse Effects
Background Information/Case Definitions
Laboratories
Miscellaneous Guidelines
Data & Surveillance
Variants – Omicron
Testing
Symptoms/Treatment
COVID-19 Diagnosis in Children
Post-COVID-19 Condition
Case Investigation & Contact Tracing
Infection Prevention and Control
Section II: Guidelines for Health Sectors
Healthcare Providers
First Responders, Dentistry, Pharmacy, and Allied Health
Death Services
Congregate Living (including Long-Term Care, Prisons, and Shelters)
Section III: Guidelines for the Community
Travel, Transport & Borders
Schools / Childcare
Mental Health /Addiction /Inequity
Community
Businesses/Workplaces
Masks (Non-Medical)
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca

Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- Statement from the Chief Public Health Officer of Canada [04-12-2022]
  - “With a shift to more targeted testing, a range of other indicators, from laboratory test positivity and wastewater surveillance to daily numbers of people in hospitals and critical care continue to be important for ongoing monitoring trends. Not unexpectedly, the increase in in-person activities following easing of public health measures, together with spread of the more transmissible BA.2 sub-lineage of Omicron and some waning of immunity, are likely all contributing to increased transmission. Although provincial and territorial (P/T) reporting frequency and intervals vary, recent 7-day averages (ranging 7-days ending from April 2-11, 2022 across P/Ts) show an ongoing marked increase in average daily case counts, as well as rising trends in severe illness in most jurisdictions. Likewise, laboratory test positivity during the latest 7-day period (April 4-10, 2022) increased to 19% nationally, and community wastewater data continue to signal sharply rising trends in a number of localities across the country. Keeping infection rates down remains key to protecting vulnerable populations, reducing severe outcomes and dampening the overall impact on the health system. As we expect the SARS-CoV-2 virus to continuously evolve, we are closely monitoring the domestic and international situation and preparing for new variants of concern. Currently, the BA.2 sub-lineage of the Omicron variant accounts for 61% of recent viruses sequenced in Canada and is steadily increasing. However, while BA.2 is dominant in several jurisdictions, its distribution varies across the country. The growth rate of BA.2 internationally appears to be highest where there is a combination of low booster dose coverage and where the BA.1 sub-lineage has not already driven high infection rates during the Omicron wave. While BA.2 is even more transmissible than the BA.1 sub-lineage of Omicron, it appears to have a similar severity and symptom profile. Currently, evidence indicates that getting an mRNA COVID-19 vaccine booster dose can provide longer-lasting protection and better effectiveness, even if you have been previously infected with COVID-19.”

- NACI: Updated guidance on a first booster dose of COVID-19 vaccines in Canada [04-12-2022]
  - Summary of National Advisory Committee on Immunization (NACI) Statement of April 12, 2022 [04-12-2022]

- Canada COVID-19 weekly epidemiology report: 27 March to 2 April 2022 (week 13) [04-08-2022]

- Vaccine coverage: This report was last updated on April 8, 2022 with data up to and including April 3, 2022.
  - 85.59% of the population 5 years and older are fully vaccinated

- COVID-19 rapid testing and screening in workplaces: what employers should know [updated 03-16-2022]

- Mathematical modelling and COVID-19 [updated regularly]

- COVID-19 daily epidemiology update [updated regularly]
- **COVID-19 data trends** [updated regularly]

**BC Centre for Disease Control | bccdc.ca**
  - COVID-19 mRNA vaccine COMIRNATY® (Pfizer) (adult/adolescent) [updated 04-13-2022]
  - COVID-19 mRNA vaccine SPIKEVAX™ (Moderna) [updated 04-13-2022]
  - COVID-19 vaccine VAXZEVRATM/COVISHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 04-13-2022]
  - COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 04-13-2022]

- Clinical practice guide for the use of therapeutics in mild-moderate COVID-19 [updated 04-12-2022]
- Practice tool #1: step-by-step assessment for clinicians [updated 04-12-2022]
- Practice tool #2: definitions of clinically extremely vulnerable (CEV) [updated 04-12-2022]
- Health care provider information on Paxlovid, remdesivir and sotrovimab [updated 04-12-2022]

**Institut national de santé publique | inspq.qc.ca**
- SRAS-CoV-2 - Capsules vidéo sur les recommandations de PCI pour les milieux de soins [04-13-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les cliniques médicales/cliniques externes/cliniques de dépistage COVID-19/GMF [04-12-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les milieux de soins de courte durée [04-12-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les milieux de soins psychiatriques [04-12-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les soins à domicile [04-12-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les unités d’hémodialyse [04-12-2022]
- SRAS-CoV-2 : Définitions des termes en prévention et contrôle des infections dans les milieux de soins [04-12-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les centres d’hébergement et de soins de longue durée [04-12-2022]
- Vigie des cas du syndrome inflammatoire multisystémique de l’enfant liés ou non à la COVID-19, au Québec, du début de la pandémie au 31 janvier 2022 [04-11-2022]

**CDC: Centers for Disease Control and Prevention | cdc.gov**
- Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022 [04-14-2022]
- COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022 [04-14-2022]
- Non-U.S. citizen, Non-U.S. immigrants: air travel to the United States [04-14-2022]
- Requirement for proof of COVID-19 vaccination for air passengers [04-14-2022]
- Cases in the U.S. [04-13-2022]
- Overall US COVID-19 vaccine distribution and administration update as of Wed, 13 Apr 2022 06:00:00 EST [04-13-2022]
- Vaccinating children with disabilities against COVID-19 [04-13-2022]
- COVID-19 forecasts: deaths [04-13-2022]
- Previous COVID-19 forecasts: hospitalizations [04-13-2022]
- COVID-19 vaccines for moderately to severely immunocompromised people [04-12-2022]
- Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19–associated hospitalization among adults with previous SARS-CoV-2 infection — United States, June 2021–February 2022 [04-12-2022]
- COVID-19 vaccine side effects in children and teens [updated 04-06-2022]
- COVID data tracker weekly review: interpretive summary for April 8, 2022 [04-08-2022]
- EARLY RELEASE: COVID-19 mortality and vaccine coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022 [04-08-2022]
- Notes from the field: SARS-CoV-2 Omicron variant infection in 10 persons within 90 days of previous SARS-CoV-2 Delta variant infection — four states, October 2021–January 2022 [04-07-2022]
- Interim considerations for health departments for SARS-CoV-2 testing in homeless shelters and encampments [04-06-2022]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

- COVID-19 situation update worldwide, as of week 14, updated 14 April 2022 [04-14-2022]
- Communicable disease threats report, 10-16 April 2022, week 15 [04-13-2022]
- Communicable disease threats report, 3-9 April 2022, week 14 [04-08-2022]
- COVID-19 situation update worldwide, as of week 13, updated 7 April 2022 [04-07-2022]
- Country overview report: week 13 2022 [04-07-2022]
- Data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country [updated regularly]
- Data on COVID-19 vaccination in the EU/EEA [updated regularly]

FDA: U.S. Food & Drug Administration | fda.gov

- Coronavirus (COVID-19) update: daily roundup [updated regularly]
- In vitro diagnostics EUAs - antigen diagnostic tests for SARS-CoV-2 [updated 04-07-2022]

Public Health England | gov.uk

Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”

- Location of Public Health England (PHE) functions from 1 October 2021

World Health Organization | who.int

- WHO Director-General’s opening remarks on Member State Information Session on COVID-19 [04-14-2022]
"This week, the COVID-19 IHR Emergency Committee met and unanimously agreed that the pandemic remains a public health emergency. I appreciated their advice and agree that far from being the time to drop our guard, this is the moment to work even harder to save lives. Specifically this means investing so that COVID-19 tools are equitably distributed and we simultaneously strengthen health systems as outlined in the 2022 WHO Strategic Preparedness and Response Plan, which we will be discussing today. It remains of major concern that large numbers of health workers and others at high risk are still unvaccinated. Today, only 30% of healthcare workers and 20% of people aged 60 or older have been vaccinated in low-income countries. Equitable access to vaccination of the most at-risk groups remains the single most powerful tool we have to save lives. Striving to vaccinate 70% of the population of every country remains essential for bringing the pandemic under control, with priority given to health workers, older people and other at-risk groups. Bridging the vaccine equity gap is the best way to boost population immunity and insulate against future waves."

- WHO Director-General’s opening remarks at the WHO press conference [04-13-2022]
- “Over the past two years, WHO has continued to update its clinical management of COVID-19 guidelines and hone its recommendations based on the latest science. Treatments including oxygen, corticosteroids and antivirals are helping to further break the link between COVID-19 infection and death. Diagnostics are also improving and becoming more accessible. However, just as I said last year that trickle down vaccination is not an effective strategy for fighting a deadly respiratory virus; trickle-down treatment and testing are similarly reckless. Diagnosing at-risk patients early enough for new antivirals to be effective is essential and should be available to everyone, everywhere. In addition, higher testing and sequencing rates will be vital for tracing existing and identifying new variants as they emerge. WHO scientists continue to work with thousands of experts around the world to track and monitor the SARS-CoV-2 virus. At present there are a number of Omicron sub-lineages we’re following closely, including BA.2, BA.4 and BA.5 and another recombinant detected, made up of BA.1 and BA.2. This virus has over time become more transmissible and it remains deadly especially for the unprotected and unvaccinated that don’t have access to health care and antivirals. The best way to protect yourself is to get vaccinated and boosted when recommended. Continue wearing masks — especially in crowded indoor spaces. And for the indoors, keep the air fresh by opening windows and doors, and invest in good ventilation.”

- Coronavirus disease (COVID-19) weekly epidemiological update [04-12-2022]
- Log of major changes and errata in WHO daily aggregate case and death count data [updated regularly]
- Draft landscape and tracker of COVID-19 candidate vaccines [updated regularly]
- Coronavirus disease (COVID-2019) press briefings [audio posted first; transcripts posted later]
- EPI-WIN: WHO information network for epidemics [updated regularly]

Other relevant government bodies / health care organizations
- Government of Ontario
  - Ontario expanding access to COVID-19 antivirals [04-11-2022]
- Canada Border Services Agency
The Canada Border Services Agency reminds boaters of entry and reporting requirements [updated 04-14-2022]

Canadian Centre for Occupational Health and Safety (CCOHS)
- COVID-19 health and safety resources [updated 04-13-2022]
- Coronavirus (COVID-19) – tips: education providers: grades K – 12 [updated 02-17-2022]
- Coronavirus (COVID-19) – tips: daycares [updated 02-17-2022]

Health Canada
- Health professional risk communication: distribution of EVUSHIELD (tixagevimab and cilgavimab for injection) with English-Only Vial and Carton Labels [updated 04-14-2022]
- Reducing COVID-19 risk in community settings: a tool for operators [updated 02-10-2022]

Indigenous Services Canada
- Coronavirus (COVID-19) and Indigenous communities [updated regularly]

Statistics Canada
- COVID-19: a data perspective [updated regularly]
- Provisional death counts and excess mortality, January 2020 to January 2022 [04-14-2022]
- Many shelters for victims of abuse see increases in crisis calls and demand for external supports in the first year of the COVID-19 pandemic [04-12-2022]
- Leading indicator of international arrivals to Canada, March 2022 [04-11-2022]

National Institute on Ageing
- My COVID-19 visit risk [no date]

UK Health Security Agency
- SARS-CoV-2 variant of concern diagnostic assurance [updated 04-14-2022]
- Weekly statistics for NHS Test and Trace (England): 31 March to 6 April 2022 [updated 04-14-2022]
- COVID-19 vaccine weekly surveillance reports (weeks 39 to 14, 2021 to 2022) [updated 04-14-2022]
- Consensus statements on COVID-19 [updated 04-14-2022]
- The R value and growth rate [updated 04-14-2022]
- NHS Test and Trace statistics (England): methodology [updated 04-14-2022]
- Reducing the spread of respiratory infections, including COVID-19, in the workplace [updated 04-14-2022]
- Living safely with respiratory infections, including COVID-19 [updated 04-13-2022]
- COVID-19 variants: genotypically confirmed case numbers [updated 04-13-2022]
- People with symptoms of a respiratory infection including COVID-19 [04-12-2022]
- REACT-1 study of coronavirus transmission: March 2022, final results [04-11-2022]
- COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [updated 04-11-2022]
- COVID-19 rapid lateral flow test kit instructions: throat and nose test [updated 04-11-2022]
- **COVID-19 rapid lateral flow test kit instructions: SureScreen** [updated 04-11-2022]
- **How to do a coronavirus (COVID-19) rapid lateral flow test** [updated 04-11-2022]
- **COVID-19 test validation approved products** [updated 04-11-2022]

- **UK Department of Health and Social Care**
  - **Thousands more patients to access second ground-breaking antiviral** [04-12-2022]

- **UK Department for Education**
  - **Attendance in education and early years settings during the coronavirus (COVID-19) pandemic** [04-12-2022]

- **UK Department for Transport**
  - **Transport use during the coronavirus (COVID-19) pandemic** [updated 04-13-2022]

- **UK Environment Agency**
  - **Environment Agency waterways: coronavirus (COVID-19) updates** [updated 04-14-2022]

- **UK Medicines and Healthcare products Regulatory Agency**
  - **Valneva COVID-19 vaccine approved by MHRA** [04-14-2022]
  - **Regulatory approval of COVID-19 Vaccine Valneva** [updated 04-14-2022]
  - **MHRA approves the Moderna COVID-19 vaccine ‘Spikevax’ for use in 6 to 11-year olds** [updated 04-14-2022]
  - **Medical devices given exceptional use authorisations during the COVID-19 pandemic** [updated 04-14-2022]
  - **Coronavirus (COVID-19) vaccines adverse reactions** [updated 04-14-2022]

- **UK Office for Health Improvement and Disparities**
  - **COVID-19 mental health and wellbeing surveillance: report** [updated 04-12-2022]

- **UK Office for National Statistics**
  - **Coronavirus (COVID-19) infection survey, UK: 14 April 2022** [04-14-2022]

- **UK Ofsted**
  - **Reported COVID-19 notifications by registered early years and childcare settings** [updated 04-12-2022]

- **UK Scientific Advisory Group for Emergencies**
  - **CMMID: Network properties of the school system in England – implications for the effect of school reopening strategies on transmission of SARS-COV-2, 4 June 2020** [04-08-2022]

- **Centre for Global Infectious Disease Analysis**
  - **Report 51 - Valuing lives, education and the economy in an epidemic: societal benefit of SARS-CoV-2 booster vaccinations in Indonesia** [02-14-2022]

---

**CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu**

- **Fourth COVID vaccine dose gives 76% added protection against death** [04-14-2022]
- **News Scan for Apr 14, 2022: Health worker COVID exposures; COVID-19 and those at risk for heart disease; More avian flu in 5 states**
- **Global COVID cases fall as CDC extends travel mask order** [04-13-2022]
- **Pandemic cut US life span almost 2 years, more than any peer nation** [04-13-2022]
News Scan for Apr 13, 2022: Casirivimab-imdevimab for COVID; COVID-19 transmission in households; More avian flu in Midwest

Estimate: Less than half the world has had COVID-19 [04-12-2022]

Officials closely track rising COVID levels in Northeastern states [04-12-2022]

News Scan for Apr 12, 2022: COVID-19 and myocarditis; COVID-related loss of smell; More avian flu in the Dakotas

Shanghai tweaks lockdown as COVID-19 surge presses on [04-11-2022]

Study details COVID’s toll on essential workers, health workers [04-11-2022]

News Scan for Apr 11, 2022: COVID-19 and elder mental health; Risk factors for COVID-related syndrome; H5N6 avian flu case in China; Global flu rebound; Polio in Africa

National Collaborating Centre for Environmental Health | ncceh.ca

April, 2022 environmental health research scan (with COVID-19 section) [04-05-2022]

March, 2022 environmental health research scan (with COVID-19 section) [03-16-2022]

The Omicron variant - updating our knowledge as the surge subsides [02-15-2022]

ProMED | promedmail.org

Latest on COVID-19 [individual posts]


COVID-19 update (95): essential workers, mental health, risk factors, ABs, WHO [04-12-2022]


COVID-19 update (93): blood clots, fluvoxamine, pulse oximetry, South Asia, WHO [04-08-2022]

Updated Daily

COVID-19 resources (case counts) | arcgis.com

Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG

COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu

2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]

Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org

Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]

Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]

Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]
Guidelines and Technical documents (updated weekly)

The guidelines listings are current to 04-14-2022; posted 04-14-2022

Section I: General Guidelines

Ontario / Canada Main Page

- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario

- ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)

- CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
- BC B.C.'s response to COVID-19 [updated 04-12-2022]
- AB COVID-19 public health actions [no date]
- SK Living with COVID [no date]
- MB Manitoba Pandemic Response System [no date]
- QC About the measures in force [no date]
- NB Living with COVID-19 [no date]
- NL Current Restrictions [no date]
- PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
- NS Reopening plan [updated regularly]
- NW Restrictions and Moving Forward [no date]
- YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
- NT Nunavut’s Path: Living with COVID-19 [updated 03/25/2022]
- Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO

- Implementation guidance for assessments of frontline service readiness [07-01-2021]
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [11-04-2020]
- WHO COVID-19 preparedness and response progress report - 1 February to 30 June 2020 [08-03-2020]

UK
Vaccinations - General

Ontario Ministry of Health

- COVID-19 vaccine-relevant information and planning resources [updated 04-06-2022]
- Ethical framework for COVID-19 vaccine distribution [updated 03-31-2022]
- Guidance for routine immunization services during COVID-19 version 2 [10-28-2021]

Canada (Federal)

- Planning guidance for immunization clinics for COVID-19 vaccines [03-30-2022]
- COVID-19 vaccine guide for youth and adults (12 years and over): Overview [02-02-2022]
- Adjusting public health measures in the context of COVID-19 vaccination [02-02-2022]
- An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
- NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
- For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-16-2021]
- COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
- Health care provider vaccine tool kit. version 2 [05-07-2021]
- Planning guidance for administration of COVID-19 vaccine [12-21-2020]
- Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
- Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
- Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)

- BC Spikevax™ (Moderna) [updated 04-04-2022]
- BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 04-04-2022]
- BC Vaxzevria™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 04-04-2022]
• BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) [updated 04-04-2022]
• BC COVID-19 Vaccine ChAdOx1-S [recombinant] [updated 04-04-2022]
• BC COVID-19 vaccine eligibility [updated 04-04-2022]
• BC Novavax shipping, storage and use guidelines [03-04-2022]
• BC Novavax redistribution guidelines [03-04-2022]
• BC Immunization manual: summary of changes: admin circular [03-04-2022]
• BC COVID-19 vaccine eligibility [updated 04-04-2022]
• BC Pfizer redistribution guidelines [02-08-2022]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [01-31-2022]
• BC Point of care risk assessment (PCRA) [no date]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [01-31-2022]
• BC Janssen shipping, storage and use guideline [01-17-2022]
• BC Janssen redistribution guidelines [01-17-2022]
• BC Regulated and unregulated health professionals SARS-CoV-2 immunization order [01-09-2022]
• BC Emergency medical assistants SARS-CoV-2 immunization order [updated 01-09-2022]
• BC Moderna redistribution guidelines [01-06-2022]
• BC Administrative circular [12-31-2021]
• BC 2021/22 seasonal influenza vaccine eligibility [10-00-2021]
• BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [10-15-2021]
• BC Latex content in vaccines [10-00-2021]
• BC Immunization manual appendix A: informed consent (page 4) [updated 09-00-2021]
• BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [08-31-2021]
• BC COVID-19 vaccination: why your 2nd dose is important [08-27-2021]
• BC Vaccine SOP: cold chain incident reporting process [updated 07-21-2021]
• BC Pfizer vaccine sub dose vial reporting [07-13-2021]
• BC COVID-19 Pfizer vaccine partial tray ULT distribution guidelines [05-19-2021]
• BC Cold chain assets warranty contact information [05-05-2021]
• BC Vaccine SOP: return of materials to manufacturers [04-30-2021]

WHO

• Injection safety in the context of coronavirus disease (COVID-19) vaccination: Addendum to policy brief, 5 April 2022 [04-05-2022]
• Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19v [03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [updated 03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [03-15-2022]
• Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: Grading of evidence – Evidence to recommendations tables [03-15-2022]
• Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience) [03-15-2022]
• Annexes to the recommendations for use of the Sinovac CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [03-15-2022]
• Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [03-15-2022]
• Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
• NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
• Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [01-21-2022]
• COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
• Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [12-09-2021]
• Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [12-09-2021]
• Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
• Injection safety in the context of coronavirus disease (COVID-19) vaccination [11-05-2021]
• Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
• Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [08-04-2021]
• COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.2 [06-10-2021]
• Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
• Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
• Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief [05-26-2021]
• Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
• AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
• AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine [05-10-2021]
- Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
- COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
- Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
- COVID-19 and mandatory vaccination: ethical considerations and caveats [04-13-2021]
- Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
- Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
- Stay up to date with your COVID-19 vaccines [updated 04-02-2022]
- COVID-19 vaccine booster shots [updated 04-01-2022]
- Understanding Viral Vector COVID-19 Vaccines [updated 03-14-2022]
- Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 02-02-2022]
- COVID-19 vaccine reporting systems [updated 01-04-2022]
- Communication resources for COVID-19 vaccines [12-11-2021]
- COVID-19 vaccination clinical & professional resources [12-01-2021]
- COVID-19 vaccination program operational guidance [10-14-2021]
- Public health investigations of COVID-19 vaccine breakthrough cases: Case investigations protocol [no date]
- Interim guidance for routine and influenza immunization services during the COVID-19 Pandemic [04-15-2021]
- Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]

UK
- National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [updated 04-01-2022]
- National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine [updated 04-01-2022]
- National protocol for Spikevax (formerly COVID-19 vaccine Moderna) [updated 04-01-2022]
- Monitoring reports of the effectiveness of COVID-19 vaccination [updated 03-25-2022]
- COVID-19 vaccination programme [updated 03-17-2022]
- COVID-19 vaccination: information for healthcare practitioners [updated 03-10-2022]
- COVID-19 vaccination: vaccine product information [02-23-2022]
- COVID-19 vaccination: blood clotting information for healthcare professionals [updated 02-14-2022]
- COVID-19 vaccination: booster dose resources [updated 02-02-2022]
- National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [11-20-2021]
- COVID-19 vaccination: what to expect after vaccination [updated 11-09-2021]
- Monitoring of the effectiveness of COVID-19 vaccination [09-14-2021]
- COVID-19: vaccine surveillance strategy [03-29-2021]

ECDC
- Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update [03-14-2022]
- Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA [01-31-2022]
- Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA [12-14-2021]
- Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA [10-15-2021]
- Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0 [10-08-2021]
- Interim public health considerations for the provision of additional COVID-19 vaccine doses [09-01-2021]
- Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence [07-22-2021]
- Countering online vaccine misinformation in the EU/EEA [06-29-2021]
- Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making [05-18-2021]
- Objectives of vaccination strategies against COVID-19 [04-23-2021]
- Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions [04-21-2021]
- Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice [03-29-2021]
- Stress test on logistical aspects of COVID-19 vaccination deployment plans: final report [02-03-2021]
- Integrated COVID-19 response in the vaccination era [02-01-2021]
- COVID-19 vaccination and prioritisation strategies in the EU/EEA [12-22-2020]

Australia
- ATAGI recommendations on the use of a booster dose of COVID-19 vaccine [updated 03/28/2022]
- Clinical recommendations for COVID-19 vaccines [updated 03/25/2022]
- COVID-19 vaccination – information on COVID-19 Pfizer (COMIRNATY) vaccine [updated 03-28-2022]
- ATAGI clinical guidance for COVID-19 vaccine providers [02/23/2022]
- COVID-19 vaccination – vaccine dose policy [updated 02-07-2022]
Vaccinations - Specific populations

Canada (Federal)

- NACI rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age [modified 03-24-2022]
- NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age [archived] [modified 03-17-2022]
- COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [modified 03-11-2022]
- NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [modified 02-09-2022]
- Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview [modified 02-03-2022]
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [modified 02-02-2022]
- Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [updated 01-25-2022]
- NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Provinces and territories (other than Ontario)

- BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent [updated 04-04-2022]
- BC Health professionals COVID-19 vaccination status information and preventive measures – March 7, 2022 [03-08-2022]
- BC COVID-19 vaccination for children age 5-11 frequently asked questions for community practitioners [03-07-2022]
- BC RESIDENTIAL CARE COVID–19 VACCINATION STATUS [02-28-2022]

WHO

- Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-25-2021]
- Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]
- Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC
- COVID-19 vaccines for children and teens [updated 04-07-2022]
- Resources to Promote the COVID-19 Vaccine for Children & Teens [updated 03-31-2022]
- COVID-19 vaccine equity for racial and ethnic minority groups [updated 03-29-2022]
- COVID-19 vaccines while pregnant or breastfeeding [updated 03-03-2022]
- COVID-19 vaccines for people who would like to have a baby [updated 03-03-2022]
- COVID-19 vaccination considerations for persons with underlying medical conditions [updated 02-25-2022]
- COVID-19 vaccine information for specific groups [updated 02-18-2022]
- Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [updated 01-20-2022]
- Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]
- Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [4-30-2021]

UK
- COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [updated 04-11-2022]
- COVID-19 vaccination: resources for children aged 5 to 11 years [updated 03-28-2022]
- COVID-19 vaccination: resources for children and young people aged 12 to 17 years [updated 02-01-2022]
- Interim public health considerations for COVID-19 vaccination of children aged 5-11 years [12-01-2021]
- Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

ECDC
- Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1 [02-18-2022]
- COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose [02-08-2022]
- Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA [06-01-2021]

Australia
- COVID-19 vaccination – COVID-19 vaccine information for the residential aged care workforce [03-29-2022]
- COVID-19 vaccination – COVID-19 vaccination decision guide for frail older people, including those in residential aged care facilities [updated 03-28-2022]
- COVID-19 vaccination – shared decision making guide for people receiving palliative care or end-of-life care [updated 03-28-2022]
- ATAGI – provider guide to COVID-19 vaccination of people with immunocompromise [updated 03-28-2022]
- ATAGI expanded guidance on temporary medical exemptions for COVID-19 vaccines [updated 02-25-2022]
- COVID-19 vaccination – vaccine dose policy- aged cared facilities [updated 02-07-2022]
- COVID-19 vaccination – COVID-19 vaccination decision guide for women who are pregnant, breastfeeding or planning pregnancy [updated 12-24-2021]

Vaccinations- Adverse Effects

Canada (Federal)
- National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)
- BC Guidance document on the management of inadvertent vaccine errors [02-04-2022]
- BC Guidance on the Management of Inadvertent COVID-19 Vaccine Errors [02-04-2022]
- BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
- BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
- BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]
- BC Clinical care guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome (TTS) [04-30-2021]

CDC
- COVID-19 vaccine side effects in children and teens [updated 04-06-2022]

- Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination [02-11-2022]
- Possible side effects after getting a COVID-19 vaccine [01-12-2022]
- Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [reviewed 08-09-2021]

WHO
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- How to monitor and report COVID-19 vaccine side effects [03-15-2021]

UK
- Coronavirus (COVID-19) vaccine adverse reactions [updated 04-07-2022]
- COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [updated 03-21-2022]
Myocarditis and pericarditis after COVID-19 vaccination [updated 03-21-2022]
COVID-19 vaccination: Guillain-Barré Syndrome information for healthcare professionals [updated 12-17-2021]
Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

Background Information/Case Definitions

Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [01-17-2022]

PHAC
- National case definition: coronavirus disease (COVID-19) [updated 04-01-2022]
- COVID-19 case report form [01-11-2021]

CDC
- Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: background information [10-06-2021]
- COVID-19: epidemiology, virology and clinical features [10-06-2021]

Australia
- COVID-19 disease, symptoms and variants [updated 12-23-2021]

Other
- BMJ best practice COVID-19 [updated regularly]
Laboratories

Ontario Ministry of Health

- Community labs and specimen collection centres: version 3 [03-29-2020]

PHAC

- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [updated 04-12-2022]
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [11-23-2021]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

WHO

- Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19 [updated 03-24-2022]
- Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
- Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
- COVID-19 new variants: knowledge gaps and research [01-12-2021]
- Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoaassays [09-11-2020]

CDC

- How to report COVID-19 laboratory data [updated 04-04-2022]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [updated 04-04-2022]
- Testing strategies for SARS-CoV-2 [updated 04-04-2022]
- Guidance for reporting SARS-CoV-2 sequencing results [03-21-2022]
- Evaluation for SARS-CoV-2 testing in animals [updated 03-30-2022]
- Guidance for general laboratory safety practices during the COVID-19 pandemic [updated 03-02-2022]
- Using antibody tests for COVID-19 [updated 02-24-2022]
- **Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings** [updated 01-24-2022]
- **Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19)** [12-13-2021]
- **Frequently asked questions on COVID-19 testing for laboratories** [11-12-2021]
- **Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity** [10-29-2021]
- **Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19** [10-25-2021]
- **Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination** [08-09-2021]
- **Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing** [06-30-2021]
- **Variants and genomic surveillance for SARS-CoV-2** [04-02-2021]
- **Resources for laboratories working on coronavirus (COVID-19)** [03-28-2021]
- **Information for laboratories about coronavirus (COVID-19)** [03-28-2021]
- **SARS-CoV-2 viral culturing at CDC** [12-29-2020]
- **Serology testing for COVID-19 at CDC** [11-03-2020]

**UK**

- **Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [updated 04-04-2022]
- **National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests** [updated 04-04-2022]
- **Technical validation protocol for SARS-CoV-2 nucleic acid detection** [updated 04-04-2022]
- **Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [updated 04-04-2022]
- **Coronavirus (COVID-19) testing in adult care homes** [updated 04-01-2022]
- **NHS test and trace statistics (England): methodology** [updated 03-18-2022]
- **How tests and testing kits for coronavirus (COVID-19) work** [updated 02-14-2022]
- **Surge testing for new coronavirus (COVID-19) variants** [updated 08-16-2021]
- **Maintaining records of staff, customers and visitors to support NHS Test and Trace** [07-20-2021]
- **COVID-19: guidance for sampling and for diagnostic laboratories** [03-29-2021]

**ECDC**

- **The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates** [05-10-2021]

**Australia**

- **PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)** [01-28-2022]

**Other**

- **BC PHO order on health authority regulated health professionals SARS-CoV-2 swabbing** [11-16-2020]
• BC PHO order on midwives and certified practice speech language pathologists SARS-CoV-2 swabbing [11-16-2020]
• BC PHO order on British Columbia emergency health services SARS-CoV-2 swabbing [11-16-2020]

Miscellaneous Guidelines

PHAC

• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [updated 04-08-2022]
• COVID-19 and people with disabilities in Canada [updated 04-04-2022]
• Individual and community-based measures to mitigate the spread of COVID-19 in Canada [02-02-2022]
• COVID-19: safety advice for private indoor gatherings [12-23-2021]

Canadian provinces and territories (other than Ontario)

• BC COVID-19 ethical decision-making framework [12-24-2020]

WHO

• Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
• Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
• ACT-Accelerator ‘fair share asks’ - by country [02-09-2022]
• WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
• Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
• Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
• Critical preparedness, readiness and response actions for COVID-19: interim guidance [05-27-2021]

CDC

• Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals [reviewed 01-31-2022]
• Public health guidance for potential COVID-19 exposure associated with travel [updated 01-27-2022]
• Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [updated 01-21-2022]
• RRT composition: COVID-19 considerations [03-01-2021]
• Managing investigations during an outbreak [07-31-2020]
• Optimizing supply of PPE and other equipment during shortages [07-16-2020]

ECDC
• One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
• Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]
• Conducting in-action and after-action reviews of the public health response to COVID-19 [06-04-2020]

Australia
• CDNA National guidelines for public health units [updated 03-22-2022]

Other
• Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]

Data & Surveillance

Canada
• COVID-19 data trends [modified 04-08-2022]
• Mathematical modelling and COVID-19 [modified 04-01-2022]
• National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO
• WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [updated 02-15-2022]
• Public health surveillance for COVID-19: interim guidance [updated 02-14-2022]
• End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance [01-31-2022]
• Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States [01-21-2022]

CDC
• Wastewater surveillance data reporting & analytics [updated 04-08-2022]
• National wastewater surveillance system (NWSS) [updated 03-21-2022]
• Wastewater surveillance testing methods [01-26-2022]
• Public health interpretation and use of wastewater surveillance data [01-26-2022]
• Developing a wastewater surveillance sampling strategy [01-26-2022]
• Targeted wastewater surveillance at facilities, institutions, and workplaces [01-26-2022]
• COVID-19 serology surveillance [03-11-2021]
• Data visualization [02-16-2021]
• Large-scale geographic seroprevalence surveys [10-02-2020]

ECDC
• Organisation of vector surveillance and control in Europe [12-13-2021]
• Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
• Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30) [11-29-2021]
• COVID-19 variants: genomically confirmed case numbers [updated 11-29-2021]
• Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
• COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
• Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]

UK
• COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]

Variants – Omicron

Canada
• SARS-CoV-2 variants: national definitions, classifications and public health actions [03-09-2022]

Ontario Ministry of Health
• COVID-19 interim guidance: Omicron surge management of critical staffing shortages in highest risk settings. Version 4.0 [updated 04-11-2022]

CDC
• Omicron variant: what you need to know [updated 03-29-2022]

UK
• Investigation of SARS-CoV-2 variants: technical briefings [updated 04-08-2022]
• SARS-CoV-2 variants of public health interest [updated 04-08-2022]
• COVID-19: investigation and initial clinical management of possible cases [updated 03-25-2022]
• SARS-CoV-2 Omicron VOC: investigating and managing suspected or confirmed cases [updated 12-23-2021]
• Methods for the detection and characterisation of SARS-CoV-2 variants – first update [12-20-2021]

ECDC
• Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update [updated 01-27-2022]
• Threat assessment brief: implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update [12-02-2021]
• Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
• Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]

WHO
• Enhancing readiness for Omicron (B.1.529): technical brief and priority actions for member stats [updated 01-21-2022]

Testing

Canada
• Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [updated 09-08-2021]
- **Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection** [02-23-2021]
- **Guidance for repeated PCR testing in individuals previously positive for COVID-19** [12-08-2020]
- **National polymerase chain reaction (PCR) testing indication guidance for COVID-19** [10-07-2020]

**Ontario Ministry of Health**
- **COVID-19 test requisition** [06-12-2021]
- **Considerations for privately-initiated testing. version 3.0** [05-21-2021]
- **COVID-19 guidance: considerations for rapid antigen screening. Version 2.0** [02-17-2021]
- **Considerations for employer rapid antigen screening pilot** [11-20-2020]

**Canadian provinces and territories (other than Ontario)**
- BC **COVID-19: viral testing guidelines for British Columbia** [updated 03-23-2022]
- BC **COVID-19 infection prevention and control: guidance for test collection & assessment centres** [09-09-2021]
- BC **Infection prevention and control guidance for test collection and assessment centres** [09-09-2021]
- BC **Antibody testing (serology) page** [no date]
- BC **Guideline for the appropriate use of SARS-CoV-2 (COVID-19) antibody (serology) testing** [08-14-2020]

**WHO**
- **Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing** [03-09-2022]

**CDC**
- **Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community** [updated 04-04-2022]
- **Testing strategies for SARS-CoV-2** [updated 04-04-2022]
- **Guidance for SARS-CoV-2 point-of-care and rapid testing** [updated 04-04-2022]
- **Using antibody tests for COVID-19** [updated 02-24-2022]
- **SARS-CoV-2 antigen testing in long term care facilities** [updated 02-17-2022]
- **Interim guidance for SARS-CoV-2 testing in correctional and detention facilities** [updated 02-15-2022]
- **Overview of testing for SARS-CoV-2 (COVID-19)** [updated 02-11-2022]
- **Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic** [updated 02-02-2022]
- **Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes: nursing homes & long-term care facilities** [updated 02-02-2022]
- **CDC’s diagnostic test for COVID-19 only and supplies** [10-05-2021]
- **Guidance for health departments about COVID-19 testing in the community** [08-30-2021]
- **CDC diagnostic tests for covid-19** [08-07-2021]
- **Nucleic acid amplification tests (NAATS)** [06-14-2021]
- **Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing** [06-14-2021]
- **Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings** [03-29-2021]
Serology testing for COVID-19 at CDC [11-03-2020]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [updated 04-08-2022]
- SARS-CoV-2 variants of public health interest [updated 04-08-2022]
- Investigation of SARS-CoV-2 variants of concern: variant risk assessments [updated 03-25-2022]
- Testing for coronavirus (COVID-19) before hospital [updated 03-08-2022]
- Coronavirus COVID-19 serology and viral detection tests: technical validation reports [updated 02-18-2022]
- How tests and testing kits for coronavirus (COVID-19) work [updated 02-14-2022]
- Investigation of SARS-CoV-2 variants of concern: technical briefings [09-17-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021 [07-16-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021 [07-16-2021]
- SARS-CoV-2 variant of concern diagnostic assurance [07-15-2021]
- SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence [10-16-2020]

ECDC
- Considerations for the use of antibody tests for SARS-CoV-2 – first update [02-10-2022]
- Methods for the detection and identification of SARS-CoV-2 variants- first update [12-20-2021]
- Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories [12-20-2021]
- Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK [10-26-2021]
- Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings [05-06-2021]
- Considerations for the use of saliva as sample material for COVID-19 testing [05-03-2021]
- Considerations on the use of self-tests for COVID-19 in the EU/EEA [03-17-2021]
- Guidance for COVID-19 quarantine and testing of travellers [03-12-2021]
- Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA [02-16-2021]
- Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update [02-15-2021]
- COVID-19 testing strategies and objectives [09-18-2020]
- Objectives for COVID-19 testing in school settings [08-10-2020]

Australia
- PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [updated 02-02-2022]
- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Symptoms/Treatment

Canada
- Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply [modified 02-24-2022]
- COVID-19 for health professionals: treatments [modified 02-01-2022]
• COVID-19 signs, symptoms and severity of disease: a clinician guide [modified 12-09-2021]
• Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health
• COVID-19 reference document for symptoms v. 14.0 [updated 04-11-2022]
• COVID-19 patient screening guidance document version 5.0 [08-26-2021]

WHO
• Living guidance for clinical management of COVID-19 [11-23-2021]
• COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
• Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
• WHO living guideline: drugs to prevent COVID-19 [03-02-2021]
• Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC
• Caring for post-COVID conditions [updated 03-21-2022]
• Clinical care quick reference for COVID-19 [updated 03-16-2022]
• Care for breastfeeding people: Interim Guidance on Breastfeeding and Breast Milk Feeds in the Context of COVID-19 [updated 02-25-2022]
• Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 02-15-2022]
• Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 [updated 02-15-2022]
• If You Are Sick or Caring for Someone [02-09-2022]
• Ending home isolation for persons with COVID-19 not in healthcare settings [updated 01-14-2022]
• Ending isolation and precautions for people with COVID-19: interim guidance [updated 01-14-2022]
• Standard operating procedure (SOP) for triage of suspected COVID-19 patients in non-US healthcare settings: early identification and prevention of transmission during triage [10-18-2021]
• Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
• Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [02-16-2021]
• Assessing risk factors for severe COVID-19 illness [11-30-2020]

WHO
• Therapeutics and COVID-19 [updated 03-03-2022]
• COVID-19 clinical care pathway (CARE): confirm, assess, respond, evaluate [02-04-2022]
COVID-19 clinical care pathway (CARE): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery [02-04-2022]


Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [07-15-2021]

Hypertension and COVID-19 [06-17-2021]

WHO Information note: COVID-19 considerations for tuberculosis (TB) care [05-05-2021]

Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

WHO COVID-19 clinical care bundle [04-23-2021]

Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance [08-13-2020]

US NIH

COVID-19 treatment guidelines [updated 04-08-2022]

UK

COVID-19: migrant health guide [updated 03-08-2022]

COVID-19: long-term health effects [04-30-2021]

Australia

Coronavirus (COVID-19) – identifying the symptoms [last updated 11-11-2020]

Back to Top

COVID-19 Diagnosis in Children

Canada

COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children (MIS-C) [12-09-2021]

WHO


CDC

Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [05-20-2021]

Other

BC Children with immune compromise [11-30-2021]


BC Pediatric clinical guidance for COVID-19 [09-27-2021]


BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]

BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]
**Post-COVID-19 Condition**

**Canada**
- Post COVID-19 condition [09-24-2021]

**Ontario**
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

**WHO**
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

**CDC**
- Caring for post-COVID conditions [03-21-2022]
- Post-COVID conditions: information for healthcare providers [07-09-2021]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

**UK**
- Long-term effects of coronavirus (long COVID) [03-31-2022]

**Case Investigation & Contact Tracing**

**Canada**
- Public health management of cases and contacts associated with COVID-19 [updated 04-12-2022]

**Ontario**
- Management of cases and contacts of COVID-19 in Ontario (version 14.0) [04-11-2022]

**Canadian provinces and territories (other than Ontario)**
- BC Interim guidance: public health management of cases and contacts associated with novel coronavirus (COVID-19) in the community [03-16-2022]

**WHO**
- Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [02-17-2022]
- Considerations for quarantine of contacts of COVID-19 cases [06-25-2021]
- Operational guide for engaging communities in contact tracing [05-28-2021]
- Contact tracing in the context of COVID-19 [02-01-2021]

**CDC**
- Quarantine and isolation [03-30-2022]
- Contact tracing resources for health departments [03-25-2022]
- Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [02-28-2022]
- Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-28-2021]
- Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-28-2022]

Coronavirus Disease 2019 (COVID-19): 04/14/2022 Compiled by PHO Library Services 29
• Schools, child care, and colleges [02-07-2022]
• Contact tracing for COVID-19 [02-10-2022]
• Investigating a COVID-19 case [01-21-2022]
• Ending home isolation for persons with COVID-19 not in healthcare settings [01-14-2022]
• COVID-19 contact tracing communications toolkit for health departments [11-05-2021]
• Global contact tracing [01-15-2021]

UK
• People with symptoms of a respiratory infection including COVID-19 [04-01-2022]
• COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [03-30-2022]

ECDC
• Contact tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – 4th update [10-28-2021]
• Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions [06-28-2021]

Infection Prevention and Control

PHAC / Health Canada
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [03-25-2022]
• Coronavirus disease (COVID-19): prevention and risks [03-22-2022]
• Infection prevention and control for COVID-19: interim guidance for outpatient and ambulatory care settings [01-25-2022]
• Infection prevention and control for COVID-19: interim guidance for home care settings [01-25-2022]
• Infection prevention and control for COVID-19: interim guidance for acute healthcare settings [01-25-2022]
• Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [01-07-2022]
• Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed– December 23, 2021 [12-24-2021]
• At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]
• COVID-19 medical masks and N95 respirators: overview [11-29-2021]
• COVID-19: guidance on indoor ventilation during the pandemic [01-18-2021]

Ontario
• Infection prevention and control hubs [11-10-2020]

Canadian provinces and territories (other than Ontario)
• BC COVID-19: outbreak management protocol for acute care settings [02-02-2022]
WHO

- Annex to Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [10-01-2021]
- Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [07-12-2021]
- Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]

CDC

- Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes [02-02-2022]
- Considerations for inpatient obstetric healthcare settings [11-19-2021]
- Cleaning and disinfecting your facility: every day and when someone is sick [11-15-2021]

ECDC

- Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination [03-29-2021]
- Infection prevention and control and preparedness for COVID-19 in healthcare settings- sixth update [02-09-2021]

UK

- COVID-19: infection prevention and control (IPC) [03-15-2022]
- Technical specifications for personal protective equipment (PPE) [02-14-2022]
- COVID-19: guidance for stepdown of infection control precautions and discharging COVID-19 patients from hospital to home settings [01-17-2022]
- Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [09-15-2021]

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health

- COVID-19 guidance: acute care v.7 [02-16-2022]
- COVID-19 guidance: primary care providers in a community setting: version 10.0 [02-14-2022]

Canada

- COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]
WHO
- COVID-19 home care bundle for health care workers [02-09-2022]
- Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
- Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
- Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: Interim guidance [07-07-2021]
- COVID-19: occupational health and safety for health workers: interim guidance [02-02-2021]

CDC
- Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [01-21-2022]
- Staff shortages [01-21-2022]
- Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings [01-14-2022]

UK
- COVID-19: managing healthcare staff with symptoms of a respiratory infection [04-01-2022]
- Contract tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – fourth update [10-28-2021]

First Responders, Dentistry, Pharmacy, and Allied Health
Ontario Ministry of Health

PHAC
- Evidence to support safe return to clinical practice by oral health professionals in Canada during the COVID-19 pandemic: a report prepared for the Office of the Chief Dental Officer of Canada Ontario Ministry of Health [02-02-2022]

WHO
- Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19): interim guidance [02-17-2021]

CDC
- Evaluation for SARS-CoV-2 testing in animals [03-30-2022]

UK
- Emergency planning and response for education, childcare, and children's social care settings [04-08-2022]

Other
• **COVID-19: guidance for the use of teledentistry** Royal College of Dental Surgeons of Ontario [no date]

**Death Services**

**Ontario**

• [ON Bereavement Authority of Ontario COVID-19](#) [03-17-2022]

**WHO**

• Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance [09-04-2020]

**CDC**

• Collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19: interim guidance [04-04-2022]
• Recommendations for Tribal ceremonies & gatherings [09-30-2021]

**UK**

• Handling the deceased with suspected or confirmed COVID-19 [04-01-2022]

**Other**

• QC COVID-19: preventive and protective measures for funeral services businesses [07-30-2021]

---

**Congregate Living (including Long-Term Care, Prisons, and Shelters)**

**Ontario Ministry of Health**

• [COVID-19 guidance: congregate living for vulnerable populations, Version 3](#) [updated 03-30-2022]
• [COVID-19 screening tool for long-term care homes and retirement homes: version 10](#) [03-18-2022]
• [COVID-19 guidance: long-term care homes and retirement homes for public health units, Version 4](#) [02-03-2022]
• [Retirement homes policy to implement directive #3](#) [12-27-2021]
• [COVID-19 guidance: home and community care providers: version 6](#) [05-21-2021]

**PHAC**

• Infection prevention and control for COVID-19: interim guidance for long term care homes [01-25-2022]
• [COVID-19: guidance on pets and long-term care homes](#) [07-20-2021]
• [Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes](#) [04-12-2021]
• [COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities](#) [04-14-2020]

**WHO**

• Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]
CDC
- Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments [updated 04-06-2022]
- How to protect yourself and others [02-25-2022]
- Recommendations for quarantine duration in correctional and detention facilities [02-15-2022]
- Investigating cases in homeless shelters [02-10-2022]
- Interim guidance on people experiencing unsheltered homelessness [02-10-2022]
- Correctional and detention facilities [02-10-2022]
- Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [02-10-2022]
- Infection control for nursing homes [02-02-2022]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]
- Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [04-30-2021]
- Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]

UK
- Flu and acute respiratory illness in prisons and secure settings: information for staff [04-06-2021]
- COVID-19: guidance for hostel services for people experiencing homelessness and rough sleeping [updated 04-04-2022]
- Visiting someone in prison [04-01-2022]
- COVID-19: admission and care of people in care homes [03-22-2022]
- Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [03-21-2022]
- COVID-19: provision of night shelters [03-10-2022]
- Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1 [02-18-2022]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
- COVID-19: national framework for prison regimes and services [08-18-2021]
- COVID-19 guidance for prison settings v 1.0 [07-16-2021]
- Infection control in prisons and places of detention [07-01-2011]

Canadian provinces and territories (other than Ontario)
- BC Visitor guidance for long-term care and seniors' assisted living [updated 03-18-2022]
- BC COVID-19 outbreak management protocol for long-term care and seniors’ assisted living settings [02-02-2022]

Other
- CSC Testing of inmates in federal correctional institutions for COVID-19 [updated 04-12-2022]

Back to Top
Section III: Guidelines for the Community
Travel, Transport & Borders
Ontario Ministry of Health
- Travelling during COVID-19 [03-21-2022]
- Guidance for public transit agencies and passengers in response to COVID-19 [03-21-2022]

Canada
- Official global travel advisories [updated often]
- COVID-19: travel, testing, quarantine and borders [updated 04-11-2022]
- Provincial and territorial restrictions [03-17-2022]
- COVID-19: exposure notices from select cruise ships [03-11-2022]
- Guidance material for air operators managing travellers during the check-in procedure for flights departing from an aerodrome in Canada [11-16-2021]
- Federal safety guidance to protect drivers and limit the spread of COVID-19 in commercial vehicle operations [06-24-2021]

CDC
- COVID-19 travel recommendations by destination [updated regularly]
- Requirement for proof of COVID-19 vaccination for air passengers [updated 04-04-2022]
- Stay up to date with your COVID-19 vaccines [04-02-2022]
- Non-U.S. citizen, Non-U.S. immigrants: air travel to the United States [01-27-2022]
- Requirement for proof of negative COVID-19 test or recovery from COVID-19 for all air passengers arriving in the United States [01-27-2022]
- Required testing before air travel to the US [01-27-2022]

WHO
- An implementation guide for the management of COVID-19 on board cargo ships and fishing vessels [12-23-2021]
- WHO public health checklist for controlling the spread of COVID-19 in ships, sea ports and inland ports [10-00-2021]

UK
- People with symptoms of a respiratory infection including COVID-19 [updated 04-12-2022]
- Coronavirus (COVID-19): advice for heavy goods (HGV) and public service vehicle (PSV) operators [03-29-2022]
- Carry out international road haulage [03-18-2022]
- Travel abroad from England during coronavirus (COVID-19) [03-18-2022]
- Coronavirus (COVID-19): cruise ship travel [03-17-2022]
- Travel to England from another country during coronavirus (COVID-19) [03-18-2022]

Other
- Emergency response plan and action checklist for use by air carriers in the event of a public health emergency [no date]
**Schools / Childcare**

Ontario Ministry of Health

- Management of cases and contacts of COVID-19 in Ontario [04-11-2022]
- COVID-19: health and safety measures at schools [03-31-2022]
- COVID-19: health and safety measures for child care [03-31-2022]
- COVID-19 safety guidelines for: camps [03-01-2022]

PHAC

- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [02-02-2022]
- Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [01-07-2022]
- COVID-19: organized summer activities for children and youth [12-16-2021]

CDC

- Considerations for institutions of higher education [02-07-2022]
- Schools, child care, and colleges [updated 02-07-2022]
- COVID-19 guidance for operating early care and education/child care programs [01-28-2022]
- Guidance for COVID-19 prevention in K-12 schools [01-13-2022]

UK

- Emergency planning and response for education, childcare, and children's social care settings [04-08-2022]

**Mental Health /Addiction /Inequity**

Ontario Ministry of Health

- COVID-19: mental health resources for camp operators version 1.0 [07-13-2021]
- Guidance for consumption and treatment services sites: version 2 [04-16-2020]

PHAC

- Helping people who use substances during the COVID-19 pandemic [07-06-2021]

Provinces & Territories (excluding Ontario)

- AB Harm reduction and COVID-19: guidance document for community service providers [12-08-2020]
- BC COVID-19: provincial episodic overdose prevention service (e-OPS) protocol [06-26-2020]

WHO

- Mental health and COVID-19: Early evidence of the pandemic’s impact: Scientific brief, 2 March 2022 [03-02-2022]
• **Rise, respond, recover: renewing progress on women's, children's and adolescent's health in the era of COVID-19** [12-00-2021]
• **Social isolation and loneliness among older people: advocacy brief** [07-29-2021]
• **Smoking and COVID-19** [06-30-2020]
• **Addressing violence against children, women and older people during the COVID-19 pandemic: key actions** [06-18-2020]
• **COVID-19 and violence against women: what the health sector / system can do** [04-07-2020]

**CDC / SAMHSA**
• **Substance abuse and mental health training and technical assistance related to COVID-19** [08-16-2021]
• **Virtual recovery resources** [07-00-21]
• **Disaster planning handbook for behavioural health service programs** [03-00-2021]
• **Interim guidance for syringe services programs** [05-15-2020]
• **Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020** [05-07-2020]
• **Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020** [03-19-2020]
• **Intimate partner violence and child abuse considerations during COVID-19** [no date]

**UK**
• **Alcohol and drug misuse prevention and treatment guidance** [03-07-2022]
• **Every Mind Matters: looking after your mental health** [no date]
• **Domestic abuse: how to get help** [11-11-2021]

**Other**
• **QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing** [04-05-2022]
• **QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action** [05-04-2022]
• **QC Preventing loneliness in young adults in the context of a pandemic** [04-05-2022]
• **Public health ethics and COVID-19: selected resources** [11-00-2021]
• **Risk mitigation in the context of dual public health emergencies, Version 1.5** [03-00-20]

**Community**

**Ontario Ministry of Health**
• **COVID-19 public health measures and advice** [03-21-2022]
• **Guidance on community emergency evacuations: version 2** [07-06-2021]

**PHAC**
• **COVID-19 and people with disabilities in Canada** [04-04-2022]
• **Reducing COVID-19 risk in community settings: a tool for operators** [02-10-2022]
Individual and community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada [02-02-2022]

Accessing additional public health support for First Nations and Inuit communities during COVID-19 [01-28-2022]

COVID-19: organized summer activities for children and youth [12-16-2021]

At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

WHO

Key planning recommendations for mass gatherings in the context of COVID-19 [11-04-2021]

CDC

Information about COVID-19, pets, and other animals [03-31-2022]

Operational considerations for community isolation centers [updated 03-30-2022]

Breastfeeding & caring for newborns [01-20-2022]

Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-04-2021]

COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity [08-21-2020]

Considerations for owners and operators of multifamily housing including populations at increased risk for complications from COVID-19 [05-05-2021]

UK

Living safely with respiratory infections, including COVID-19 [updated 04-13-2022]

COVID-19: guidance for providers of accommodation for asylum seekers [04-04-2022]

Using the NHS COVID Pass to demonstrate COVID-19 status [04-01-2022]

Infection prevention and control in adult social care: COVID-19 supplement [03-31-2022]

Other

QC Measures to reduce sedentary behaviour and encourage physical activity in persons 65 and older living at home during the COVID-19 pandemic [04-05-2022]

AUS Early aero-medical evacuation of COVID-19 cases and contacts from remote communities [08-20-2020]

Businesses/Workplaces

Ontario Ministry of Health

COVID-19 and workplace health and safety [03-28-2022]

Changes to public health and workplace safety measures [03-21-2022]

COVID-19 worker and employee screening [03-21-2022]

Restaurant and food services health and safety during COVID-19 [01-31-2022]

COVID-19 guidance: workplace outbreaks v2.0 [10-05-2021]

Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization [11-30-2021]

WHO

Preventing and mitigating COVID-19 at work [05-19-2021]
Coronavirus Disease 2019 (COVID-19) - 04/14/2022
Compiled by PHO Library Services

**CDC**
- Workplaces & businesses: plan, prepare and respond [10-18-2021]
- Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

**UK**
- Reducing the spread of respiratory infections, including COVID-19, in the workplace [04-04-2022]
- Infection prevention and control in adult social care: COVID-19 supplement [03-31-2022]

**Masks (Non-Medical)**

**Ontario Ministry of Health**
- Face coverings and face masks [03-31-2022]

**PHAC**
- COVID-19 mask use: advice for community settings [02-01-2022]

**WHO**
- What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? [00-00-2021]
- Mask use in the context of COVID-19 [12-01-2020]

**CDC**
- Your guide to masks [02-25-2022]
- Use of masks to help slow the spread of COVID-19 [08-12-2021]

**ECDC**
- Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern [02-07-2022]
- Use of gloves in healthcare and non-healthcare settings in the context of the COVID-19 pandemic [07-02-2020]

**UK**
- Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [04-13-2022]
- The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]

**Other**
- BC Face coverings (COVID-19) [12-03-2021]